The median overall survival for SCC patients with high tumor cell VEGFR2 expression was 24.7 months, and for those with a low tumor cell VEGFR2 expression (H-score <10), was 92.8 months (3.7-fold difference, n = 25, Fig 7L). The gene discussed is KDR; the disease is neoplasm.